

DAFTAR PUSTAKA

- Aletti, G. D, Gostout, B. S., Podratz, K. C., Cliby, W. A. (2006) 'Ovarian cancer surgical resectability: Relative impact of disease, patient status, and surgeon', *Gynecol. Oncol.*, 100(1), pp. 33–37. doi: 10.1016/j.ygyno.2005.07.123.
- Andrijono, Hidayat Y.M., Mihardja, S.G., Siregar, B. (2008) 'Hubungan ekspresi Her-2 / neu dan p53 terhadap respons terapi dan kelangsungan hidup penderita kanker ovarium jenis epitel', *Maj Obstet Ginekol Indones.*, 32(4), pp. 193–205. doi: 10.1016/j.bpobgyn.2016.08.006.
- Anwar, L. S., Haryono, S.J., Aryandono, T., Haryana, S.M. (2017) 'Micro-RNA: Biogenesis, Fungsi, dan perannya dalam Proses Karsinogenesis dan Penatalaksanaan Kanker'. Yogyakarta: Gadjah Mada University Press.
- Aziz, M. F. (2009) 'Gynecological cancer in Indonesia', *J. Gynecol. Oncol.*, 20(1), pp. 8–10. doi: 10.3802/jgo.2009.20.1.8.
- Bamias, A., Sotiropoulou, M., Zagouri, F., Trachana, P., Sakellariou, K., Kostouros, E., Kakoyianni, K., Rodolakis, A., Vlahos, G., Haidopoulos, D., Thomakos, N., Antsaklis, A., Dimopoulos, M. A. (2012) 'Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: Cell type is the most useful prognostic factor', *Eur. J. Cancer*, 48(10), pp. 1476–1483. doi: 10.1016/j.ejca.2011.09.023.
- Barry, J. A., Azizia, M. M., Hardiman, P. J. (2014) 'Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: A systematic review and meta-analysis', *Hum. Reprod. Update*, 20(5), pp. 748–758. doi: 10.1093/humupd/dmu012.
- Bergamini, A., Candiani, M., Taccagni, G., Rabaiotti, E., Vigan, R., De Marzi, P., Ferrari, D., Mangili, G. (2015) 'Different Patterns of Disease Spread between Advanced-Stage Type I and II Epithelial Ovarian Cancer', *Gynecol. Obstet. Invest.*, doi: 10.1159/000381261.

- Braem, M. G. M., Onland-Moret, N. C., Van Den Brandt, P. A., Goldbohm, R. A., Peeters, P. H. M., Kruitwagen, R. F. P. M., Schouten, L. J. (2010) 'Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study', *Am. J. Epidemiol.*, 172(10), pp. 1181–1189. doi: 10.1093/aje/kwq264.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R., Torre, L., Jemal, A. (2018) 'Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.', *CA A J. Clin.*, doi: 10.3322/caac.21492.
- Bristow, R. E. (2009) 'Predicting surgical outcome for advanced ovarian cancer, surgical standards of care, and the concept of kaizen', *Gynecol. Oncol.*, 112(1), pp. 1–3. doi: 10.1016/j.ygyno.2008.10.002.
- Buscaglia, L. E. B., Li, Y. (2011) 'Review Hallmarks of Cancer Apoptosis MiR-21 Targets', *Chin. J. Cancer*, pp. 371–380.
- Camean, M.M., Sanchez E.D., Pinera A., Diestro, M.D., Santiago, J.D., Zapardiel, I. (2016) 'The role of surgery in advanced epithelial ovarian cancer,' *Ecancermedicalscience*, vol. 10, pp. 1–13.
- Chan, J. K., Blansit, K., Kiet, T., Sherman, A., Wong, G., Earle, C., Bourguignon, L. Y. W. (2014) 'Gynecologic Oncology The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer', *Gynecol. Oncol.*, Elsevier B.V., 132(3), pp. 739–744. doi: 10.1016/j.ygyno.2014.01.034.
- Chang, S. J., Hodeib, M., Chang, J., Bristow, R. E. (2013) 'Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis', *Gynecol. Oncol.*, Elsevier Inc., 130(3), pp. 493–498. doi: 10.1016/j.ygyno.2013.05.040.
- Chéreau, E., Ballester, M., Selle, F., Cortez, A., Darai, E., Rouzier, R.. (2010) 'Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer', *Am. J. Obstet.*, Elsevier Inc., 202(2), p. 178.e1-178.e10. doi: 10.1016/j.ajog.2009.10.856.
- Chi, D. S., Venkatraman, E.S., Masson, V., Hoskins, W. J. (2000) 'The ability of

- preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.’, *Gynecol. Oncol.*, 77(2), pp. 227–31. doi: 10.1006/gyno.2000.5749.
- Chi, D. S., Liao, J. B., Leon, L. F., Venkatraman, E. S., Hensley, M. L., Bhaskaran, D., Hoskins, W. J. (2001) ‘Identification of prognostic factors in advanced epithelial ovarian carcinoma.’, *Gynecol. Oncol.*, 82(3), pp. 532–7. doi: 10.1006/gyno.2001.6328.
- Chi, D., Eisenhauer, E., Zivanovic, O., Sonoda, Y., Abu-Rustum, N. R., Levine, D. A., Guile, M. W., Bristow, R. E., Aghajanian, C., Barakat, R. R., (2009) ‘Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm’, *Gynecol. Oncol.*, Elsevier Inc., 114(1), pp. 26–31. doi: 10.1016/j.ygyno.2009.03.018.
- Chim, S. S. C., Shing, T. K. F., Hung, E. C. W., Leung, T. Y., Lau, T. K., Chiu, R. W. K., Lo, Y. M. D. (2008) ‘Detection and characterization of placental microRNAs in maternal plasma’, *Clin. Chem.*, 54(3), pp. 482–490. doi: 10.1373/clinchem.2007.097972.
- Chornokur, G., Amankwah, E. K., Schildkraut, J. M., Phelan, C. M. (2013) ‘Gynecologic Oncology Global ovarian cancer health disparities’, *Gynecol. Oncol.*, Elsevier Inc., 129(1), pp. 258–264. doi: 10.1016/j.ygyno.2012.12.016.
- Chow S., Shao J., Wang H., (2008) *Sample Size Calculations in Clinical Research* 2nd ed. Chapman & Hall/ CRC Biostatistics Series. pp. 177.
- Cibula, D., Gompel, A., Mueck, A. O., La Vecchia, C., Hannaford, P. C., Skouby, S. O., Zikan, M., Dusek, L. (2010) ‘Hormonal contraception and risk of cancer’, *Hum. Reprod. Update*, 16(6), pp. 631–650. doi: 10.1093/humupd/dmq022.
- Cibula, D., Widschwendter, M., Majek, O., Dusek, L. (2011) ‘Tubal ligation and the risk of ovarian cancer: Review and meta-analysis’, *Hum. Reprod. Update*, 17(1), pp. 55–67. doi: 10.1093/humupd/dmq030.
- Cittelly, D. M., Dimitrova, I., Howe, E. N., Cochrane, D. R., Jean, A., Spoelstra, N. S., Post, M. D., Lu, X., Broaddus, R. R., Spillman, M. a., Richer, J. K.

- (2012) 'Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel', *Mol. Cancer Ther.*, 11(December), pp. 2556–2566. doi: 10.1158/1535-7163.MCT-12-0463.
- Clark, T. G., Stewart, M. E., Altman, D. G., Gabra, H., Smyth, J. F. (2001) 'A prognostic model for ovarian cancer', *Br. J. Cancer*, 85(7), pp. 944–952. <http://www.ncbi.nlm.nih.gov/pubmed/11592763>.
- Deb, B., Uddin, A., Chakraborty, S. (2018) 'miRNAs and ovarian cancer: An overview', *J. Cell. Physiol.*, 233(5), pp. 3846–3854. doi: 10.1002/jcp.26095.
- Denoyelle, C., Lambert, B., Meryet-Figuière, M., Vigneron, N., Brotin, E., Lecerf, C., Abeilard, E., Giffard, F., Louis, M. H., Gauduchon, P., Juin, P., Poulain, L. (2014) 'MiR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation', *Cell Death Dis.*, 5(10). doi: 10.1038/cddis.2014.389.
- Ding, X., Park, S. I., McCauley, L. K., Wang, C. Y. (2013) 'Signaling between transforming growth factor β (TGF- β) and transcription factor snai2 represses expression of Microrna mir-203 to promote epithelial-Mesenchymal transition and tumor metastasis', *J. Biol. Chem.*, 288(15), pp. 10241–10253. doi: 10.1074/jbc.M112.443655.
- Du, B., Wang, Z., Zhang, X., Feng, S., Wang, G., He, J., Zhang, B. (2014) 'MicroRNA-545 suppresses cell proliferation by targeting cyclin D1 and CDK4 in lung cancer cells', *PLoS ONE*, 9(2), pp. 1–9. doi: 10.1371/journal.pone.0088022.
- Du, J., Li B., Fang, Y., Liu, Y., Wang, Y., Li, J., Zhou, W., Wang, X. (2015) 'Overexpression of Class III β -tubulin, Sox2, dan Nuclear Survivin is Predictive of Taxane Resistance in Patients with Stage III Ovarian Epithelial Cancer' *BMC Cancer*, 15:536. doi: [10.1186/s12885-015-1553-x](https://doi.org/10.1186/s12885-015-1553-x)
- Ezzati, M., Abdullah, A., Sharifabrizi, A., Hou, J., Kopf, M., Stedman, J. K., Samuelson, R., Shahabi, S. (2014a) 'Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma', *Int. Sch. Res. Not.*, 2014, pp. 1–10. doi: 10.1155/2014/953509.

- Fagotti, A., Ferrandina, G., Fanfani, F., Garganese, G., Vizzielli, G., Carone, V., Scambia, G. (2008) 'Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma,' *Am. J. Obstet. Gynecol.*, vol. 199, no. 6.
- Felder, M., Arvinder, K., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J., Hu, K., Shojaei, H., J Whelan, R., S Patankar, M. (2014) 'MUC16 (CA-125)-Tumor Biomarker to Cancer Therapy, a work in progress', *Mol. Cancer*, 13(129), pp. 1–15. doi: 10.1186/1476-4598-13-129.
- Feng, X., Wang, Z., Fillmore, R., Xi, Y. (2014) 'MiR-200, a new star miRNA in human cancer', *Cancer Lett*, 344(2), pp. 166–173. doi: 10.1016/j.canlet.2013.11.004.
- Feng, Y. H., Tsao, C. J. (2016) 'Emerging role of microRNA-21 in cancer', *Biomed. Reports*, 5(4), pp. 395–402. doi: 10.3892/br.2016.747.
- Ferrara, N. (2002) 'VEGF and the quest for tumour angiogenesis factors', *Nat. Rev. Cancer*, 2(10), pp. 795–803. doi: 10.1038/nrc909.
- Folsom, A. R., Anderson, J. P., Ross, J. A. (2004) 'Estrogen replacement therapy and ovarian cancer.', *Epidemiology*, 15(1), pp. 100–4. doi: 10.1097/01.ede.0000091606.31903.8e.
- Fransisca, N., Nuryanto, H. K. (2016) 'Epidemiology Data of Ovarian Cancer in Dr . Cipto Mangunkusumo Hospital , Jakarta', *Indones J. Obs. Gynecol.*, 4(2), pp. 101–106.
- Fraser, M., Leung, B., Jahani-asl, A., Yan, X., Thompson, W. E., Tsang, B. K. (2003) 'Chemoresistance in human ovarian cancer : the role of apoptotic regulators Ovarian Cancer and Chemoresistance', *BMC*, 13, pp. 1–13.
- Friebel, T. M., Domchek, S. M., Rebbeck, T. R. (2014) 'Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers : A Systematic Review and Meta-Analysis', *J Natl Cancer Inst.*, 106(6). doi: 10.1093/jnci/dju091.
- Gadducci, A., Cosio, S. (2009) 'Surveillance of patients after initial treatment of ovarian cancer', *Crit. Rev. Oncol. Hematol.*, 71(1), pp. 43–52. doi: 10.1016/j.critrevonc.2008.12.008.

- Gao, Y., Wu, J. (2015) 'MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer', *Tumor Biol.*, Elsevier Masson SAS, (300), pp. 4843–4850. doi: 10.1007/s13277-015-3138-3.
- Gates, M. A., Rosner, B. A., Hecht, J. L., Tworoger, S. S. (2010) 'Original Contribution Risk Factors for Epithelial Ovarian Cancer by Histologic Subtype', *Am J Epidemiol.*, 171(1), pp. 45–53. doi: 10.1093/aje/kwp314.
- Hanahan, D., Weinberg, R. A. (2011) 'Hallmarks of cancer: The next generation', *Cell*, Elsevier Inc., 144(5), pp. 646–674. doi: 10.1016/j.cell.2011.02.013.
- Hatley, M. E., Patrick, D. M., Garcia, M. R., Richardson, J. A., Bassel-Duby, R., van Rooij, E., Olson, E. N. (2010) 'Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21', *Cancer Cell*. Elsevier Inc., 18(3), pp. 282–293. doi: 10.1016/j.ccr.2010.08.013.
- Hennessy, B. T., Coleman, R. L., Markman, M. (2009) 'Ovarian cancer.', *Lancet*. Elsevier Ltd, 374(9698), pp. 1371–1382. doi: 10.1016/S0140-6736(09)61338-6.
- Herzog, T. J., Spetzler, D., Xiao, N., Burnett, Ken, Maney, T., Voss, A., Reddy, S., Burger, R., Krivak, T., Powell, M., Friedlander, M., McGuire, W. (2016) 'Impact of molecular profiling on overall survival of patients with advanced ovarian cancer', *Oncotarget*, 7(15), pp. 19840–19849. doi: 10.18632/oncotarget.7835.
- Jiang, X., Tang, H., Chen, T. (2018) 'Epidemiology of gynecologic cancers in China,' *J. Gynecol. Oncol.*, vol. 29, no. 1, pp. 1–7, 2018.
- Kalluri, R., Weinberg, R. A. (2009) 'Review series The basics of epithelial-mesenchymal transition', *J. Clin. Invest.* 119(6), pp. 1420–1428. doi: 10.1172/JCI39104.1420.
- Kinose, Y., Sawada, K., Nakamura, K., Kimura, T. (2014) 'The Role of MicroRNAs in Ovarian Cancer'. *BioMed Res Int.*, Hindawi Publishing Corporation, 2014. doi: 10.1155/2014/249393.
- Kong, W., Yang, H., He, L., Zhao, J.-j., Coppola, D., Dalton, W. S., Cheng, J. Q. (2008) 'MicroRNA-155 Is Regulated by the Transforming Growth

- Factor /Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA', *Mol. Cell. Biol.*, 28(22), pp. 6773–6784. doi: 10.1128/MCB.00941-08.
- Koutsaki, M., Libra, M., Spandidos, D. A., Zaravinos, A. (2017) 'The miR-200 family in ovarian cancer', *Oncotarget*, 8(39), pp. 66629–66640. doi: 10.18632/oncotarget.18343.
- Krivak, T. C., Lele, S., Richard, S., Secord, A. A., Leath, C. A., Brower, S. L., Tian, C., Moore, R. G., Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D., Verweij, J., Ledermann, J. A., Kristeleit, R. S., Prahm, K. P., Karlsen, M. A., Hogdall, E., Scheller, N. M., Lundvall, L., Nedergaard, L., Christensen, I. J., Hogdall, C., Taylor, P. T, Haverstick, D. (2014) 'Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).', *Ann. Oncol.*, Elsevier Ltd, 136(2), p. 151; author reply 152. doi: 10.1093/jnci/dji027.
- Kurman, R. J., Shih, I. (2011) 'Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer — Shifting the paradigm', *Hum. Pathol.* Elsevier Inc., 42(7), pp. 918–931. doi: 10.1016/j.humpath.2011.03.003.
- Kurman, R. J., Shih, I. M. (2016) 'The dualistic model of ovarian carcinogenesis revisited, revised, and expanded', *Am. J. Pathol.*, 186(4), pp. 733–747. doi: 10.1016/j.ajpath.2015.11.011.
- Kurta, M. L., Edwards, R. P., Moysich, K. B., McDonough, K., Bertolet, M., Weissfeld, J. L., Diergaarde, B. (2014) 'Prognosis and conditional disease-free survival among patients with ovarian cancer,' *J. Clin. Oncol.*, vol. 32, no. 36, pp. 4102–4112.
- Langhe, R., Norris, L., Abu, F., Blackshields, G., Varley, R., Harrison, A., Gleason, N., Spillane, C., Martin, C., O'Donnell, D. M., D'Arcy, T., Leary, J. O., Toole, S. O. (2015) 'A novel serum microRNA panel to discriminate benign from malignant ovarian disease', *Cancer Lett.* Elsevier Ireland Ltd, 356(2), pp. 628–636. doi:

10.1016/j.canlet.2014.10.010.

Langhe, R., Norris, L., Saadeh A., F., Blackshields, G., Varley, R., Harrison, A., Gleeson, N., Spillane, C., Martin, C., Donnell, D. M. O., Arcy, T. D., Leary, J. O., Toole, S. O. (2013) 'MiR-200c and HuR in ovarian cancer.', *Cancer Lett.* Elsevier Ireland Ltd, 11(1), p. 72. doi: 10.1158/1535-7163.MCT-12-0463.

Ledermann J. A., Kristeleit, R. S., Kew, F., Galaal, K., Bryant, A., Naik, R., Richer, J. K.. (2013) 'MiR-200c and HuR in ovarian cancer.,' *Cancer Lett.*, vol. 11, no. 1, p. 72.

Leskelä, S., Leandro-García, L. J., Mendiola, M., Barriuso, J., Inglada-Pérez, Lucia, Muñoz, I., Martínez-Delgado, B., Redondo, A., de Santiago, J., Robledo, M., Hardisson, D., Rodríguez-Antona, C. (2011) 'The miR-200 family controls β -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients', *Endocr. Relat. Cancer*, 18(1), pp. 85–95. doi: 10.1677/ERC-10-0148.

Li, D.-P., Du, C., Zhang, Z.-M., Li, G.-X., Yu, Z.-F., Wang, X., Li, P.-F, Cheng, C., Liu, Y.-P, Zhao, Y.-S. (2014) 'Breastfeeding and Ovarian Cancer Risk: a Systematic Review and Meta-analysis of 40 Epidemiological Studies', *Asian Pacific J. Cancer Prev.*, 15(12), pp. 4829–4837. doi: 10.7314/APJCP.2014.15.12.4829.

Li, M., Li, J., Ding, X., He, M., Cheng, S.-Y.. (2010) 'microRNA and Cancer', *AAPS J.*, 12(3), pp. 309–317. doi: 10.1208/s12248-010-9194-0.

Ligament, B. (2018) 'Special Section : Ovarian Cancer', pp. 28–43.

Lima, R. T., Busacca, S., Almeida, G. M., Gaudino, G., Fennell, D. A., Vasconcelos, M. H. (2011) 'MicroRNA regulation of core apoptosis pathways in cancer', *Eur. J. Cancer*, Elsevier Ltd, 47(2), pp. 163–174. doi: 10.1016/j.ejca.2010.11.005.

Lin, H.-W., Tu, Y.-Y., Lin, S. Y., Su, W.-J., Lin, W. L., Lin, W. Z., Wu, S.-C., Lai, Y.-L. (2011) 'Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study.' *Lancet Oncol.*, Elsevier

- Ltd, 12(9), pp. 900–904. doi: 10.1016/S1470-2045(11)70165-6.
- Liu, M. X., Chan, D. W., Ngan, H. Y. S. (2012) ‘Gynecology & Obstetrics Mechanisms of Chemoresistance in Human Ovarian Cancer at a Glance’, *Gynecol Obstet.*, 2(3), pp. 3–6. doi: 10.4172/2161-0932.1000e104.
- Liu, W., Zhang, K., Wei, P., Hu, Y., Peng, Y., Fang, X., He, G., Wu, L., Chao, M., Wang, J. (2018) 'Correlation between miR-200 Family Overexpression and Cancer Prognosis,' *Hindawi*, vol. 2018.
- Livak, K. J., Schmittgen, T. D. (2001) ‘Analysis of Relative Gene Expression Data Using Real- Time Quantitative PCR and the $2^{-\Delta\Delta CT}$ Method’, *Methods*, 408, pp. 402–408. doi: 10.1006/meth.2001.1262.
- Lou, Y. L., Guo, F., Liu, F., Gao, F. L., Zhang, P. Q., Niu, X., Guo, S. C., Yin, J. H., Wang, Y., Deng, Z. F. (2012) ‘MiR-210 activates notch signaling pathway in angiogenesis induced by cerebral ischemia’, *Mol. Cell. Biochem.*, 370(1–2), pp. 45–51. doi: 10.1007/s11010-012-1396-6.
- Lowe, K. A., Chia, V. M., Taylor, A., Malley, C. O., Kelsh, M., Mohamed, M., Mowat, F. S., Goff, B. (2013) ‘Gynecologic Oncology An international assessment of ovarian cancer incidence and mortality’, *Gynecol. Oncol.*, Elsevier Inc., 130(1), pp. 107–114. doi: 10.1016/j.ygyno.2013.03.026.
- Ma, R., Jiang, T., Kang, X. (2012) ‘Circulating microRNAs in cancer : origin , function and application’ *J. Exp. Clin. Cancer Res.*, 22(Nmp 22), pp. 1–9.
- Macfarlane, L., Murphy, P. R. (2010) ‘MicroRNA : Biogenesis , Function and Role in Cancer’, *Curr. Genomics*, pp. 537–561.
- Mahmoud, E. H., Fawzy, A., A Elshimy, R. A. (2018) ‘Serum MicroRNA-21 Negatively Relates to Expression of Programmed Cell Death-4 in Patients with Epithelial Ovarian Cancer.’, *Asian Pac. J. Cancer Prev.*, 19(1), pp. 33–38. doi: 10.22034/APJCP.2018.19.1.33.
- Marchetti, C., Kristeleit, R., McCormack, M., Mould, T., Olaitan, A., Widschwendter, M., MacDonald, N., Ledermann, J. A. (2017) ‘Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review’, *Gynecol. Oncol.* Elsevier Inc., 144(1), pp. 57–60. doi: 10.1016/j.ygyno.2016.11.001.

- Marchini, S., Cavaliere, D., Fruscio, R., Calura, E., Garavaglia, D., Nerini, I. F., Mangioni, C., Cattoretti, G., Clivio, L., Beltrame, L., Katsaros, D., Scarampi, L., Menato, G., Perego, P., Chiorino, G., Buda, A., Romualdi, C., D'Incalci, M.. (2011) 'Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: A retrospective study of two independent tumour tissue collections', *Lancet Oncol.*, 12(3), pp. 273–285. doi: 10.1016/S1470-2045(11)70012-2.
- Martinelli, E., Fattorossi, A., Raspaglio, G., Zannoni, G. F., Fanelli, M., & Gallo, D. (2018), 'Translational Oncology Preoperative Anti-Class III β -Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer,' *Trans. Onc.*, vol. 11, no. xx, pp. 358–365, 2018
- Melin, A., Lundholm, C., Malki, N., Swahn, M.-L., Sparen, P., Bergqvist, A. (2011) 'Endometriosis as a prognostic factor for cancer survival', *Int. J. Cancer*, 129(4), pp. 948–955. doi: 10.1002/ijc.25718.
- Meng, X., Müller, V., Milde-Langosch, K., Trillsch, F., Pantel, K., Schwarzenbach, H (2016) 'Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer,' *Oncotarget*, vol. 7, no. 13, 2016
- Mori, R., Wang, Q., Danenberg, K. D., Pinski, J. K., & Danenberg, P. V. (2008). Both β -actin and GAPDH are useful reference genes for normalization of quantitative RT-PCR in human FFPE tissue samples of prostate cancer. *Prostate*, 68(14), 1555–1560. <https://doi.org/10.1002/pros.20815>
- Mueller, J. J., Zhou, Q. C., Iasonos, A., O’Cearbhaill, R. E., Alvi, F. A., El Haraki, A., Eriksson, A. G. Z., Gardner, G. J., Sonoda, Y., Levine, D.A., Aghajanian, C., Chi, D. S., Abu-Rustum, N., R., Zivanovic, O. (2016) 'Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center,' *Gynecol. Oncol.*, vol. 140, no. 3, pp. 436–442, 2016.
- Muralidhar, G. G., Barbolina, M. V. (2015) 'The miR-200 family: Versatile players in epithelial ovarian cancer', *Int. J. Mol. Sci*, 16(8), pp. 16833–16847. doi: 10.3390/ijms160816833.

- Mutch, D. G., Prat, J. (2014) '2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer', *Gynecol. Oncol.*, 133(3), pp. 401–404. doi: 10.1016/j.ygyno.2014.04.013.
- Nam, E. J., Yoon, H., Kim, S. W., Kim, H., Kim, Y. T., Kim, J. H., Kim, S. (2008) 'MicroRNA expression profiles in serous ovarian carcinoma,' *Clin. Cancer Res.*, vol. 14, no. 9, pp. 2690–2695.
- Peng, Y., Dai, Y., Hitchcock, C., Yang, X., Kassiss, E. S., Liu, L., Luo, Z., Sun, H.-L., Cui, R., Wei, H., Kim, T., Lee, T. J., Jeon, Y.-J., Nuovo, G. J., Volinia, S., He, Q., Yu, J., Nana-Sinkam, P., Croce, C. M. (2013) 'Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer', *Proc. Natl. Acad. Sci.*, 110(37), pp. 15043–15048. doi: 10.1073/pnas.1307107110.
- Pichiorri, F., Suh, S. S., Rocci, A., De Luca, L., Taccioli, C., Santhanam, R., Zhou, W., Benson, D. M., Hofmainster, C., Alder, H., Garofalo, M., Di Leva, G., Volinia, S., Lin, H.-J., Perotti, D., Kuehl, M., Aqeilan, R. I., Palumbo, A., Croce, C. (2016) 'Erratum: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development (Cancer Cell (2010) 18(4) (367–381) (S1535610810003429) (10.1016/j.ccr.2010.09.005))', *Cancer Cell*. Elsevier Inc., 30(2), pp. 349–351. doi: 10.1016/j.ccell.2016.07.007.
- Piver, M. S., Frank, T. O. M. S. (2003) 'Epidemiology of Ovarian Cancer', *Diagnosis and Management of Ovarian Disorders*, pp. 209–218.
- Plagens-Rotman, K., Chmaj-Wierzchowska, K., Pięta, B., Bojar, I. (2018) 'Modifiable lifestyle factors and ovarian cancer incidence in women', *Ann. Agr. Env. Med.*, 25(1), pp. 36–40. doi: 10.5604/12321966.1233565.
- Poria, D. K., Guha, A., Nandi, I., Ray, P. S. (2016) 'RNA-binding protein HuR sequesters microRNA-21 to prevent translation repression of proinflammatory tumor suppressor gene programmed cell death 4,' *Oncogene*, vol. 35, no. 13, pp. 1703–1715.
- Prat, Belhadj, Berek, bermudez, Bhatla, Cain, Denny, Fujiwara, Hacker, Avall-

- Lundqvist, Mutch, Odicino, Pecorelli, Quinn, Seoud, Shrivastava. (2015a) 'Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum', *Cancer*, 121(19), pp. 3452–3454. doi: 10.1002/cncr.29524.
- Prat, J. (2015b) 'Ovarian, fallopian tube and peritoneal cancer staging: Rationale and explanation of new FIGO staging 2013', *Best Pract. Res. Clin. Obstet. Gynaecol.*, Elsevier Ltd, 29(6), pp. 858–869. doi: 10.1016/j.bpobgyn.2015.03.006.
- Prislei, S., Martinelli, E., Mariani, M., Raspaglio, G., Sieber, S., Ferrandina, G., Shahabi, S., Scambia, G., Ferlini, C. (2013) 'MiR-200c and HuR in ovarian cancer.', *BMC Cancer.*, 13(1), p. 72. doi: 10.1186/1471-2407-13-72.
- Ritchie, W., Rajasekhar, M., Flamant, S., Rasko, J. E. J. (2009) 'Conserved Expression Patterns Predict microRNA Targets,' *PLoS Comput. Biol.*, vol. 5, no. 9, p. e1000513, 2009.
- Rodriguez, N., Rauh-Hain, J. A., Shoni, M., Berkowitz, R. S., Muto, M. G., Feltmate, C., Horowitz, N. S. (2012) 'Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy,' *Gynecol. Oncol.*, vol. 125, no. 2, pp. 362–366
- Salani, R., Backes, F. J., Fung Kee Fung, M., Holschneider, C. H., Parker, L. P., Bristow, R. E., & Goff, B. A. (2011) 'Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations', *Am. J. Obstet. Gynecol.*, 204(6), pp. 466–478. doi: 10.1016/j.ajog.2011.03.008.
- Selcuklu, S. D., Donoghue, M. T., Spillane, C. (2009) 'miR-21 as a key regulator of oncogenic processes', *Biochem. Soc. Trans.*, 37(Pt 4), pp. 918–925. doi: 10.1042/BST0370918.
- Serkies, K., Sinacki, M., Jassem, J. (2013) 'The role of hormonal factors and endocrine therapy in ovarian cancer', *Contemp. Oncol.*, 17(1), pp. 14–19. doi: 10.5114/wo.2013.33768.

- Shi, G., Ye, D., Yao, X., Zhang, S., Dai, B., Zhang, H., Shen, Y., Zhu, Y., Zhu, Y., Xiao, W., Ma, C. (2010) 'Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells.', *Acta Pharmacol., Sin Nature Publishing Group*, 31(7), pp. 867–873. doi: 10.1038/aps.2010.48.
- Smolle, E., Taucher, V., Pichler, M., Petru, E., Lax, S., Haybaeck, J. (2013) 'Targetting Signaling Pathways in Epithelial Ovarian Cancer', *Int. J. Mol. Sci.* 14, 9536-9555; doi:10.3390/ijms14059536
- Song, I. H. (2004) 'Cancer metastasis and metastasis suppressors', *Korean J. Gastroenterol.*, 43(3), pp. 1–7. doi: 10.1038/ncb2024.miR-9.
- Sulaiman, S. A., Ab Mutalib, N.-S., Jamal, R. (2016) 'miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition', *Front. Pharmacol.*, 7(August), pp. 1–14. doi: 10.3389/fphar.2016.00271.
- Sutrisna, B., Khonsa, O., Nuranna, L. (2007) "Kesintasan Pasien Karsinoma Ovarium dan Faktor-faktor yang Mempengaruhinya di RSUPN Dr . Cipto Mangunkusumo Jakarta," *Maj. Obs. Ginekol. Indones.*, vol. 31, pp. 66–72, 2007
- Tam, K. (2011) 'The role of surgery in the management of ovarian cancer.', *Baillieres. Clin. Obstet. Gynaecol.*, 1(1), pp. 353–367. doi: 10.1016/S0950-3552(87)80059-7.
- Tan, D. S., Agarwal, R., Kaye, S. B. (2006) 'Mechanisms of transcoelomic metastasis in ovarian cancer', *Lancet Oncol.*, 7(11), pp. 925–934. doi: 10.1016/S1470-2045(06)70939-1.
- Taylor, D. D., Gercel-taylor, C. (2008) 'MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer', *Gynecol. Oncol.*, 110, pp. 13–21. doi: 10.1016/j.ygyno.2008.04.033.
- Taylor, S. E., Kirwan, J. M. (2012) 'Ovarian cancer: current management and future directions', *Obstet. Gynaecol. Reprod. Med.*, Elsevier Ltd, 22(2), pp. 33–37. doi: 10.1016/j.ogrm.2011.11.003.
- Teng, Y., Su, X., Zhang, X., Zhang, Y., Li, C., Niu, W., Liu, C., Qu, K. (2016)

- ‘miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations’, *Oncotarget*, 7(49), pp. 81621–81633. doi: 10.18632/oncotarget.13154.
- Tognon, G., Carnazza, M., Ragnoli, M., Calza, S., Ferrari, F., Gambino, A., Zizioli, V., Notaro, S., Sostegni, B., Sartori, E. (2013) ‘Prognostic factors in early-stage ovarian cancer’, *Ecancermedicalscience*, 7(1), pp. 1–16. doi: 10.3332/ecancer.2013.325.
- Trihandini, I., & Nurrika, D. (2007). *Ovarium Epithelial di Rumah Sakit Kanker Dharmais Jakarta Five-Year Survival Analysis of Epithelial Ovarian Cancer Patients of Dharmais Cancer Hospital*. Jakarta, 139–144.
- Vicus, D., Finch, A., Rosen, B., Fan, I., Bradley, L., Cass, I., Sun, P., Karlan, B., McLaughlin, J., Narod, S. A. (2010) ‘Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation’, *Gynecol. Oncol.*, Elsevier Inc., 118(2), pp. 155–159. doi: 10.1016/j.ygyno.2010.03.009.
- Vivas-mejia, P. E., Valiyeva, F., Vivas-meji, P. E. (2015) ‘Upregulation of miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1 / c-Jun Pathway Upregulation of miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1 / c-Jun Pathway’, *PLOS ONE*, 9(5), pp. 1-9. doi: 10.1371/journal.pone.0097094.
- Wang, Q., Yang. (2018) ‘The role of Pcd4 in Tumor Suppression and Protein Translation’ *Biol. Cell.*, 110 (8). doi: 10.1111/boc.201800014
- Wang, K.-C., Chang, W.-H., Lee, W.-L., Huang, N., Huang, H.-Y., Yen, M.-S., Guo, C.-Y., Wang, P.-H. (2014) ‘An increased risk of epithelial ovarian cancer in Taiwanese women with a new surgico-pathological diagnosis of endometriosis.’, *BMC cancer*, 14, p. 831. doi: 10.1186/1471-2407-14-831.
- Wang X., Wei, Z., Gao, F., Zhang, X., Zhou, C., Zhu, F., Wang, Q., Gao, Q., Ma, C., Sun, W., Kong, B., Zhang, L. (2008) “Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma,” *Anticancer Res.*, vol. 28, no. 5B, pp. 2991–2996, 2008

- Wang, Y., Gao, X. J., Wei, F., Zhang, X. W., Yu, J. P., Zhao, H., Sun, Q., Yan, F., Yan, C. H., Li, H., Ren, X. (2014) 'Diagnostic and prognostic value of circulating miR-21 for cancer: A systematic review and meta-analysis', *Gene*, 533(1), pp. 389–397. doi: 10.1016/j.gene.2013.09.038.
- Wang, Y. P., Li, K. B. (2009) 'Correlation of expression profiles between microRNAs and mRNA targets using NCI-60 data,' *BMC Genomics*, vol. 10, pp. 1–13, 2009.
- Webb, P. M., Leader, G., Jordan, S. J., Head, T., & Causes, C. (2016) 'Best Practice & Research Clinical Obstetrics and Gynaecology Epidemiology of epithelial ovarian cancer,' *Best Pract. Res. Clin. Obstet. Gynaecol.*, pp. 1–12.
- Wei, N., Liu, S. S., Chan, K. K. L., Ngan, H. Y. S. (2012) 'Tumour suppressive function and modulation of programmed cell death 4 (PDCD4) in ovarian cancer', *PLOS ONE*, 7(1), pp. 1–10. doi: 10.1371/journal.pone.0030311.
- Wentzensen, N., Poole, E. M., Trabert, B., White, E., Arslan, A. A., Patel, A. V., Tworoger, S. S. (2016) 'Ovarian cancer risk factors by histologic subtype: An analysis from the Ovarian Cancer Cohort Consortium,' *J. Clin. Oncol.*, vol. 34, no. 24, pp. 2888–2898.
- Whiteman, D. C., Michael, F. G., Cook, L. S., Daniel, W., Hartge, P., Polly, A., Nasca, P. C., Ness, R. B., Purdie, D. M., Risch, H. A. (2000) 'Multiple Births and Risk of Epithelial Ovarian Cancer', *J. Natl. Cancer Inst.*, 92(14).
- Xu, Y., Xi, Q., Ge, W., Zhang, X. (2013) 'Identification of Serum MicroRNA-21 as a Biomarker for Early Detection and Prognosis in Human Epithelial Ovarian Cancer', *Asian Pacific J. Cancer Prev.*, 14, pp. 1057–1060.
- Yan, H. L., Xue, G., Mei, Q., Wang, Y. Z., Ding, F. X., Liu, M. F., Lu, M. H., Tang, Y., Yu, H., Y., Sun, S. H. (2009) 'Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis', *EMBO J.* Nature Publishing Group, 28(18), pp. 2719–2732. doi: 10.1038/emboj.2009.214.
- Zhang, D., Jiang Y. X., Luo, S. J., Zhou, R., Jiang, Q. X., Linghu, H. (2018)

'Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer,' *Clin. Chim. Acta*, vol. 484, pp. 32–35, 2018.

Zheng, H., Liu, J.-Y., Song, F.-J., Chen, K.-X. (2013) 'Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer.', *Cancer Biol. Med.*, 10(3), pp. 123–130. doi: 10.7497/j.issn.2095-3941.2013.03.001.

Zheng, T., Wang, J., Chen, X., Liu, L. (2010) 'Role of microRNA in anticancer drug resistance', *Int. J. Cancer*, 126(1), pp. 2–10. doi: 10.1002/ijc.24782.

Zhou, B., Sun, Q., Cong, R., Gu, H., Tang, N., Yang, L., & Wang, B. (2008) 'Hormone replacement therapy and ovarian cancer risk : A meta-analysis', *Gynecol. Oncol.*, 108, pp. 641–651. doi: 10.1016/j.ygyno.2007.12.003.

Zuberi, M., Mir, R., Das, J., Ahmad, I., Javid, J., Yadav, P., Masroor, M., Ahmad, S., Ray, P. C., Saxena, A.. (2015) 'Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features', *Clin. Transl. Oncol.*, 17(10), pp. 779–787. doi: 10.1007/s12094-015-1303-1.